Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Performance comparison of next-generation sequencing platforms for determining HIV-1 coreceptor use.

Raymond S, Nicot F, Jeanne N, Delfour O, Carcenac R, Lefebvre C, Cazabat M, Sauné K, Delobel P, Izopet J.

Sci Rep. 2017 Feb 10;7:42215. doi: 10.1038/srep42215.

2.

Characterization of the Drug Resistance Profiles of Patients Infected with CRF07_BC Using Phenotypic Assay and Ultra-Deep Pyrosequencing.

Huang SW, Li WY, Wang WH, Lin YT, Chou CH, Chen M, Huang HD, Chen YH, Lu PL, Wang SF, Oka S, Chen YA.

PLoS One. 2017 Jan 20;12(1):e0170420. doi: 10.1371/journal.pone.0170420.

3.

Coreceptor usage of Chinese HIV-1 and impact of X4/DM transmission clusters among recently infected men who have sex with men.

Li X, Zhu K, Li W, Fang K, Musa TH, Song Y, Du G, Gao R, Guo Y, Yan W, Xuan Y, Zhong P, Wei P.

Medicine (Baltimore). 2016 Sep;95(39):e5017. doi: 10.1097/MD.0000000000005017.

4.

Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure.

Gonzalez-Serna A, Genebat M, De Luna-Romero M, Tarancon-Diez L, Dominguez-Molina B, Pacheco YM, Muñoz-Fernández MA, Leal M, Ruiz-Mateos E.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):6398-401. doi: 10.1128/AAC.01326-16.

PMID:
27480849
5.

Deep Sequencing of the HIV-1 env Gene Reveals Discrete X4 Lineages and Linkage Disequilibrium between X4 and R5 Viruses in the V1/V2 and V3 Variable Regions.

Zhou S, Bednar MM, Sturdevant CB, Hauser BM, Swanstrom R.

J Virol. 2016 Jul 27;90(16):7142-58. doi: 10.1128/JVI.00441-16.

6.

Evolution of coreceptor utilization to escape CCR5 antagonist therapy.

Zhang J, Gao X, Martin J, Rosa B, Chen Z, Mitreva M, Henrich T, Kuritzkes D, Ratner L.

Virology. 2016 Jul;494:198-214. doi: 10.1016/j.virol.2016.04.010.

7.

Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure.

Kyeyune F, Gibson RM, Nankya I, Venner C, Metha S, Akao J, Ndashimye E, Kityo CM, Salata RA, Mugyenyi P, Arts EJ, Quiñones-Mateu ME.

Antimicrob Agents Chemother. 2016 May 23;60(6):3380-97. doi: 10.1128/AAC.00038-16.

8.

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc.

Rodriguez C, Soulié C, Marcelin AG, Calvez V, Descamps D, Charpentier C, Flandre P, Recordon-Pinson P, Bellecave P, Pawlotsky JM, Masquelier B; ANRS AC11 Study Group..

PLoS One. 2015 Jun 11;10(6):e0127816. doi: 10.1371/journal.pone.0127816.

9.

Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc.

Sierra S, Dybowski JN, Pironti A, Heider D, Güney L, Thielen A, Reuter S, Esser S, Fätkenheuer G, Lengauer T, Hoffmann D, Pfister H, Jensen B, Kaiser R.

PLoS One. 2015 May 13;10(5):e0125502. doi: 10.1371/journal.pone.0125502.

10.
11.

Chemokine co-receptor usage in HIV-1-infected treatment-naïve voluntary counselling and testing clients in Southern Taiwan.

Tsai HC, Chou PY, Wann SR, Lee SS, Chen YS.

BMJ Open. 2015 Apr 29;5(4):e007334. doi: 10.1136/bmjopen-2014-007334.

12.

Reliable genotypic tropism tests for the major HIV-1 subtypes.

Cashin K, Gray LR, Harvey KL, Perez-Bercoff D, Lee GQ, Sterjovski J, Roche M, Demarest JF, Drummond F, Harrigan PR, Churchill MJ, Gorry PR.

Sci Rep. 2015 Feb 25;5:8543. doi: 10.1038/srep08543.

13.
14.

Retroviral vectors for analysis of viral mutagenesis and recombination.

Rawson JM, Mansky LM.

Viruses. 2014 Sep 24;6(9):3612-42. doi: 10.3390/v6093612. Review.

15.

Contribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapy.

Gibson RM, Weber J, Winner D, Miller MD, Quiñones-Mateu ME.

PLoS One. 2014 Aug 11;9(8):e104512. doi: 10.1371/journal.pone.0104512.

16.

Deep sequencing: becoming a critical tool in clinical virology.

Quiñones-Mateu ME, Avila S, Reyes-Teran G, Martinez MA.

J Clin Virol. 2014 Sep;61(1):9-19. doi: 10.1016/j.jcv.2014.06.013. Review.

17.

"Deep" sequencing accuracy and reproducibility using Roche/454 technology for inferring co-receptor usage in HIV-1.

Knapp DJ, McGovern RA, Poon AF, Zhong X, Chan D, Swenson LC, Dong W, Harrigan PR.

PLoS One. 2014 Jun 24;9(6):e99508. doi: 10.1371/journal.pone.0099508.

18.

Limited evolution of inferred HIV-1 tropism while viremia is undetectable during standard HAART therapy.

Lee GQ, Dong W, Mo T, Knapp DJ, Brumme CJ, Woods CK, Kanters S, Yip B, Harrigan PR.

PLoS One. 2014 Jun 6;9(6):e99000. doi: 10.1371/journal.pone.0099000.

19.

A genotypic HIV-1 proviral DNA coreceptor tropism assay: characterization in viremic subjects.

Brown J, Burger H, Weiser B, Pollard RB, Li XD, Clancy LJ, Baumann RE, Rogers AA, Hamdan HB, Pesano RL, Kagan RM.

AIDS Res Ther. 2014 May 21;11:14. doi: 10.1186/1742-6405-11-14.

20.

Bioinformatic analysis of HIV-1 entry and pathogenesis.

Aiamkitsumrit B, Dampier W, Antell G, Rivera N, Martin-Garcia J, Pirrone V, Nonnemacher MR, Wigdahl B.

Curr HIV Res. 2014;12(2):132-61. Review.

Items per page

Supplemental Content

Support Center